A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

ClinicalTrials.gov processed this data on March 20, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

ACTIVE, NOT RECRUITING (See Contacts and Locations)
Verified March 2024 by Exelixis

Sponsor

Exelixis

Information Provided by (Responsible Party)

Exelixis

Clinicaltrials.gov Identifier

NCT03755791
Other Study ID Numbers: XL184-312
First Submitted: November 26, 2018
First Posted: November 28, 2018
Last Update Posted: March 22, 2024
Last Verified: March 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in combination with atezolizumab versus sorafenib in adults with advanced HCC who have not received previous systemic anticancer therapy in the advanced HCC setting. The primary objective of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (PFS) and duration of overall survival (OS) versus sorafenib. The secondary objective is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.
Condition or Disease Intervention/Treatment
  • Hepatocellular Carcinoma
  • Drug: Cabozantinib
  • Drug: Cabozantinib
  • Drug: Sorafenib
  • Drug: Atezolizumab

Study Design

Study TypeInterventional
Actual Enrollment837 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Study Start DateJune 10, 2018
Actual Primary Completion DateMarch 8, 2021
Anticipated Study Completion DateDecember 1, 2024

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Experimental arm
    • Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
  • Drug: Cabozantinib
    • Supplied as 20-mg tablets; administered orally daily at 40 mg
  • Drug: Atezolizumab
    • Control arm
      • Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
    • Drug: Sorafenib
      • Single-Agent Cabozantinib arm
        • Subjects with advanced HCC will receive cabozantinib 60 mg qd
      • Drug: Cabozantinib
        • Supplied as 20-mg tablets; administered orally daily at 40 mg

      Outcome Measures

      Primary Outcome Measures

      1. Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm [Up to 27 months after the first subject is randomized. Defined as time from randomization to the earlier of progressive disease (PD) per RECIST 1.1 as determined by the Blinded Independent Radiology Committee (BIRC) or death from any cause.]
        Duration of PFS per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1)
      2. Duration of Overall Survival (OS) for the experimental arm vs. the control arm [Up to 36 months after the first subject is randomized. Defined as time from randomization to date of death from any cause.]

      Secondary Outcome Measures

      1. Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm [Up to 20 months after the first subject is randomized.]
        Duration of PFS per RECIST 1.1 by BIRC

      Eligibility Criteria

      Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
      Sexes Eligible for Study All
      Accepts Healthy Volunteers No
      Inclusion Criteria
      • Histological or cytological diagnosis of HCC or clinical diagnosis of HCC in cirrhotic patients by CT or MRI per the AASLD 2018 or EASL 2018 guidelines.
      • The subject has disease that is not amenable to a curative treatment approach (eg, transplant, surgery, ablation therapy) or locoregional therapy (eg, TACE).
      • Measurable disease per RECIST 1.1 as determined by the Investigator.
      • Barcelona Clinic Liver Cancer (BCLC) stage Category B or C.
      • Child-Pugh Score of A.
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
      Exclusion Criteria
      • Known fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.
      • Prior systemic anticancer therapy for advanced HCC including but not limited to chemotherapy, small molecule kinase inhibitors, and immune checkpoint inhibitors (ICIs). Subjects who have received local intratumoral or arterial chemotherapy are eligible; local anticancer therapy within ≥ 28 days before randomization
      • Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 8 weeks prior to randomization.
      • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 8 weeks prior to randomization.
      • Concomitant anticoagulation with oral anticoagulants

      Contacts and Locations

      Sponsors and Collaborators Exelixis
      Locations
      • Exelixis Clinical Site #208 | Phoenix, Arizona, United States, 85004
      • Exelixis Clinical Site #159 | Tucson, Arizona, United States, 85719
      • Exelixis Clinical Site #44 | La Jolla, California, United States, 92037
      • Exelixis Clinical Site #112 | Los Angeles, California, United States, 90033
      • Exelixis Clinical Site #200 | Orange, California, United States, 92868-3201
      • Exelixis Clinical Site #2 | Rialto, California, United States, 92377
      • Exelixis Clinical Site #207 | San Diego, California, United States, 92093
      • Exelixis Clinical Site #109 | San Francisco, California, United States, 94115
      • Exelixis Clinical Site #54 | San Francisco, California, United States, 94158
      • Exelixis Clinical Site #58 | Washington, District of Columbia, United States, 20007
      • Exelixis Clinical Site #191 | Miami, Florida, United States, 33125
      • Exelixis Clinical Site #4 | Atlanta, Georgia, United States, 30318
      • Exelixis Clinical Site #195 | Chicago, Illinois, United States, 60612
      • Exelixis Clinical Site #120 | Chicago, Illinois, United States, 60637
      • Exelixis Clinical Site #6 | Baltimore, Maryland, United States, 21202
      • Exelixis Clinical Site #7 | Burlington, Massachusetts, United States, 01805
      • Exelixis Clinical Site #11 | Kansas City, Missouri, United States, 64128
      • Exelixis Clinical Site #5 | Kansas City, Missouri, United States, 64131
      • Exelixis Clinical Site #8 | Saint Louis, Missouri, United States, 63110
      • Exelixis Clinical Site #1 | Las Vegas, Nevada, United States, 89169
      • Exelixis Clinical Site #14 | New Brunswick, New Jersey, United States, 08903
      • Exelixis Clinical Site #76 | Albuquerque, New Mexico, United States, 87131
      • Exelixis Clinical Site #12 | Chapel Hill, North Carolina, United States, 27599-7600
      • Exelixis Clinical Site #39 | Toledo, Ohio, United States, 43614
      • Exelixis Clinical Site #176 | Portland, Oregon, United States, 97213
      • Exelixis Clinical Site #88 | Philadelphia, Pennsylvania, United States, 19107
      • Exelixis Clinical Site #144 | Charleston, South Carolina, United States, 29425
      • Exelixis Clinical Site #199 | Dallas, Texas, United States, 75246
      • Exelixis Clinical Site #154 | Houston, Texas, United States, 77030
      • Exelixis Clinical Site #19 | Temple, Texas, United States, 76508
      • Exelixis Clinical Site #13 | Seattle, Washington, United States, 98101
      • Exelixis Clinical Site #46 | Seattle, Washington, United States, 98109
      • Exelixis Clinical Site #3 | Spokane, Washington, United States, 99208
      • Exelixis Clinical Site #217 | City of Buenos Aires, Buenos Aires, Argentina, C1118AAT
      • Exelixis Clinical Site #213 | City of Buenos Aires, Buenos Aires, Argentina, C1199ABB
      • Exelixis Clinical Site #216 | City of Buenos Aires, Buenos Aires, Argentina, C1264AAA
      • Exelixis Clinical Site #219 | Pilar, Buenos Aires, Argentina, B1629ODT
      • Exelixis Clinical Site #220 | Rosario, Santa Fe, Argentina, 2000
      • Exelixis Clinical Site #201 | Rosario, Santa Fe, Argentina, S2000CVB
      • Exelixis Clinical Site #78 | Camperdown, New South Wales, Australia, 2050
      • Exelixis Clinical Site #165 | Darlinghurst, New South Wales, Australia, 2010
      • Exelixis Clinical Site #171 | Kingswood, New South Wales, Australia, 2747
      • Exelixis Clinical Site #126 | Kogarah, New South Wales, Australia, 2217
      • Exelixis Clinical Site #155 | Westmead, New South Wales, Australia, 2145
      • Exelixis Clinical Site #142 | Greenslopes, Queensland, Australia, 4120
      • Exelixis Clinical Site #17 | Kurralta Park, South Australia, Australia,
      • Exelixis Clinical Site #107 | Box Hill, Victoria, Australia, 3128
      • Exelixis Clinical Site #166 | Heidelberg, Victoria, Australia, 3084
      • Exelixis Clinical Site #72 | Parkville, Victoria, Australia, 3050
      • Exelixis Clinical Site #190 | Nedlands, Western Australia, Australia, 6009
      • Exelixis Clinical Site #150 | Klagenfurt, Kärnten, Austria, 9020
      • Exelixis Clinical Site #137 | St. Pölten, Lower Austria, Austria, 3100
      • Exelixis Clinical Site #64 | Linz, Oberosterreich, Austria, 4010
      • Exelixis Clinical Site #198 | Graz, Steiermark, Austria, 8036
      • Exelixis Clinical Site #174 | Wien, Austria, 1090
      • Exelixis Clinical Site #50 | Brussels, California, Belgium, 1070
      • Exelixis Clinical Site #65 | Brussels, Belgium, 1200
      • Exelixis Clinical Site #169 | Edegem, Belgium, 2650
      • Exelixis Clinical Site #148 | Gent, Belgium, 9000
      • Exelixis Clinical Site #57 | Haine-Saint-Paul, Belgium, 7100
      • Exelixis Clinical Site #188 | Leuven, Belgium, 3000
      • Exelixis Clinical Site #102 | Liège, Belgium, 4000
      • Exelixis Clinical Site #184 | Salvador, BA, Brazil, 40110-060
      • Exelixis Clinical Site #89 | Belo Horizonte, MG, Brazil, 30110-022
      • Exelixis Clinical Site #98 | Belo Horizonte, MG, Brazil, 30130-090
      • Exelixis Clinical Site #113 | Curitiba, PR, Brazil, 81520-060
      • Exelixis Clinical Site #203 | Porto Alegre, RS, Brazil, 90050-170
      • Exelixis Clinical Site #175 | Barretos, SP, Brazil, 14784-400
      • Exelixis Clinical Site #121 | Jaú, SP, Brazil, 17210-120
      • Exelixis Clinical Site #186 | São Paulo, SP, Brazil, 01246-900
      • Exelixis Clinical Site #156 | São Paulo, SP, Brazil, 01321-001
      • Exelixis Clinical Site #187 | São Paulo, SP, Brazil, 01509-010
      • Exelixis Clinical Site #181 | São Paulo, SP, Brazil, 04538-132
      • Exelixis Clinical Site #91 | São Paulo, Brazil, 04543-000
      • Exelixis Clinical Site #71 | Calgary, Alberta, Canada, T2N 4N2
      • Exelixis Clinical Site #205 | Edmonton, Alberta, Canada, T6G 2B7
      • Exelixis Clinical Site #34 | Winnipeg, Manitoba, Canada, R3E 0V9
      • Exelixis Clinical Site #222 | Halifax, Nova Scotia, Canada, B3H 2Y9
      • Exelixis Clinical Site #194 | Hamilton, Ontario, Canada, L8V 5C2
      • Exelixis Clinical Site #212 | Ottawa, Ontario, Canada, K1H 8L6
      • Exelixis Clinical Site #85 | Montréal, Quebec, Canada, H3T 1E2
      • Exelixis Clinical Site #233 | Hefei, Anhui, China, 230036
      • Exelixis Clinical Site #228 | Fuzhou, Fujian, China, 350014
      • Exelixis Clinical Site #225 | Xiamen, Fujian, China, 361004
      • Exelixis Clinical Site #242 | Guangzhou, Guangdong, China, 510280
      • Exelixis Clinical Site #227 | Harbin, Heilongjiang, China, 150081
      • Exelixis Clinical Site #230 | Zhengzhou, Henan, China, 450008
      • Exelixis Clinical Site #231 | Changsha, Hunan, China, 410008
      • Exelixis Clinical Site #224 | Changsha, Hunan, China, 410013
      • Exelixis Site #241 | Changsha, Hunan, China, 410013
      • Exelixis Clinical Site #185 | Nanjing, Jiangsu, China, 210002
      • Exelixis Clinical Site #221 | Nanchang, Jiangxi, China, 330006
      • Exelixis Clinical Site #238 | Nanchang, Jiangxi, China, 330006
      • Exelixis Clinical Site #234 | Jiangyin, Jiansu, China, 214400
      • Exelixis Clinical Site #246 | Changchun, Jilin, China, 130012
      • Exelixis Clinical Site #229 | Changchun, Jilin, China, 130021
      • Exelixis Clinical Site #236 | Shenyang, Liaoning, China, 110006
      • Exelixis Clinical Site #226 | Linyi, Shandong, China, 276000
      • Exelixis Clinical Site #235 | Chengdu, Sichuan, China, 610041
      • Exelixis Clinical Site #218 | Hangzhou, Zhejiang, China, 310016
      • Exelixis Clinical Site #223 | Hangzhou, Zhejiang, China, 310022
      • Exelixis Site #239 | Beijing, China, 100034
      • Exelixis Clinical Site #237 | Beijing, China, 100050
      • Exelixis Site #240 | Shanghai, China, 200001
      • Exelixis Clinical Site #232 | Shanghai, China, 201305
      • Exelixis Clinical Site #130 | Montería, Cordoba, Colombia, 230002
      • Exelixis Clinical Site #18 | Hradec Králové, Czechia, 500 05
      • Exelixis Clinical Site #37 | Olomouc, Czechia, 779 00
      • Exelixis Clinical Site #10 | Praha 4, Czechia, 140 59
      • Exelixis Clinical Site #38 | Praha 5, Czechia, 150 06
      • Exelixis Clinical Site #43 | Amiens, France, 80054
      • Exelixis Clinical Site #27 | Besancon, France, 25030
      • Exelixis Clinical Site #56 | Bondy Cedex, France, 93140
      • Exelixis Clinical Site #29 | Caen Cedex 09, France, 14033
      • Exelixis Clinical Site #48 | Clichy, France, 92110
      • Exelixis Clinical Site #23 | Grenoble, France, 38043
      • Exelixis Clinical Site #55 | Lille Cedex, France, 59037
      • Exelixis Clinical Site #16 | Lyon Cedex 4, France, 69317
      • Exelixis Clinical Site #31 | Montbeliard, France, 25250
      • Exelixis Clinical Site #49 | Montpellier, France, 34295
      • Exelixis Clinical Site #47 | Nantes, France, 44093
      • Exelixis Clinical Site #51 | Nice, France, 06202
      • Exelixis Clinical Site #20 | Pessac, France, 33604
      • Exelixis Clinical Site #32 | Vandœuvre-lès-Nancy, France, 54511
      • Exelixis Clinical Site #69 | Batumi, Georgia, 6000
      • Exelixis Clinical Site #66 | Tbilisi, Georgia, 0112
      • Exelixis Clinical Site #68 | Tbilisi, Georgia, 0114
      • Exelixis Clinical Site #67 | Tbilisi, Georgia, 0144
      • Exelixis Clinical Site #70 | Tbilisi, Georgia, 0186
      • Exelixis Clinical Site #244 | Frankfurt, Hessen, Germany, 60590
      • Exelixis Clinical Site #210 | Kassel, Hessen, Germany, 34125
      • Exelixis Clinical Site #214 | Berlin, Germany, 13125
      • Exelixis Clinical Site #215 | Hamburg, Germany, 20246
      • Exelixis Clinical Site #146 | Hong Kong, Hong Kong,
      • Exelixis Clinical Site #42 | Hong Kong, Hong Kong,
      • Exelixis Clinical Site #9 | Hong Kong, Hong Kong,
      • Exelixis Clinical Site #140 | Budapest, Hungary, 1083
      • Exelixis Clinical Site #25 | Debrecen, Hungary, 4032
      • Exelixis Clinical Site #26 | Szeged, Hungary, 6720
      • Exelixis Clinical Site #170 | Dublin, Ireland, 8
      • Exelixis Clinical Site #30 | Jerusalem, Israel, 9112001
      • Exelixis Clinical Site #33 | Petah Tikva, Israel, 4941492
      • Exelixis Clinical Site #40 | Ramat-Gan, Israel, 5262101
      • Exelixis Clinical Site #35 | Rehovot, Israel, 7661041
      • Exelixis Clinical Site #163 | Tricase, Lecce, Italy, 73039
      • Exelixis Clinical Site #53 | Rozzano, Milano, Italy, 20089
      • Exelixis Clinical Site #158 | Bologna, Italy, 40138
      • Exelixis Clinical Site #152 | Brescia, Italy, 25124
      • Exelixis Clinical Site #147 | Milan, Italy, 20122
      • Exelixis Clinical Site #149 | Napoli, Italy, 80131
      • Exelixis Clinical Site #131 | Novara, Italy, 28100
      • Exelixis Clinical Site #167 | Roma, Italy, 00168
      • Exelixis Clinical Site #177 | Torino, Italy, 10126
      • Exelixis Clinical Site #182 | Torino, Italy, 10128
      • Exelixis Clinical Site #243 | Udine, Italy, 33100
      • Exelixis Clinical Site #157 | Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
      • Exelixis Clinical Site #127 | Suwon, Gyeonggi-do, Korea, Republic of, 16499
      • Exelixis Clinical Site #77 | Busan, Korea, Republic of, 47392
      • Exelixis Clinical Site #86 | Busan, Korea, Republic of, 49201
      • Exelixis Clinical Site #114 | Busan, Korea, Republic of, 49241
      • Exelixis Clinical Site #75 | Incheon, Korea, Republic of, 22332
      • Exelixis Clinical Site #104 | Seoul, Korea, Republic of, 03080
      • Exelixis Clinical Site #105 | Seoul, Korea, Republic of, 03080
      • Exelixis Clinical Site #99 | Seoul, Korea, Republic of, 05505
      • Exelixis Clinical Site #79 | Seoul, Korea, Republic of, 06273
      • Exelixis Clinical Site #93 | Seoul, Korea, Republic of, 06351
      • Exelixis Clinical Site #141 | Tuxtla Gutiérrez, Chiapas, Mexico, 29038
      • Exelixis Clinical Site #135 | León, Guanajuato, Mexico, 37000
      • Exelixis Clinical Site #132 | Monterrey, Nuevo Leon, Mexico, 64000
      • Exelixis Clinical Site #133 | Ciudad De México, Mexico, 06700
      • Exelixis Clinical Site #160 | Mexico City, Mexico, 06760
      • Exelixis Clinical Site #134 | San Luis Potosí, Mexico, 78250
      • Exelixis Clinical Site #153 | Veracruz, Mexico, 94300
      • Exelixis Clinical Site #92 | Maastricht, Limburg, Netherlands, 6229 HX
      • Exelixis Clinical Site #52 | Amsterdam, Noord-Holland, Netherlands, 1105 AZ
      • Exelixis Clinical Site #84 | Rotterdam, Zuid-Holland, Netherlands, 3015 GD
      • Exelixis Clinical Site #36 | Utrecht, Netherlands, 3584 CX
      • Exelixis Clinical Site #60 | Grafton, Auckland, New Zealand, 1023
      • Exelixis Clinical Site #62 | Newton, Wellington, New Zealand, 6021
      • Exelixis Clinical Site #118 | Cebu City, Philippines, 6000
      • Exelixis Clinical Site #117 | Pasig City, Philippines, 1605
      • Exelixis Clinical Site #136 | Quezon City, Philippines, 1102
      • Exelixis Clinical Site #41 | Warszawa, Mazowieckie, Poland, 02-507
      • Exelixis Clinical Site #24 | Gdansk, Pomorskie, Poland, 80-952
      • Exelixis Clinical Site #15 | Mysłowice, Slaskie, Poland, 41-400
      • Exelixis Clinical Site #204 | Cluj-Napoca, Cluj, Romania, 400015
      • Exelixis Clinical Site #211 | Cluj-Napoca, Cluj, Romania, 400015
      • Exelixis Clinical Site #202 | Cluj-Napoca, Cluj, Romania, 400641
      • Exelixis Clinical Site #206 | Bucuresti, Romania, 022328
      • Exelixis Clinical Site #209 | Iaşi, Romania, 700483
      • Exelixis Clinical Site #74 | Kislino, Kursk Region, Russian Federation, 305524
      • Exelixis Clinical Site #81 | Kaluga, Russian Federation, 248007
      • Exelixis Clinical Site #95 | Krasnodar, Russian Federation, 350040
      • Exelixis Clinical Site #108 | Moscow, Russian Federation, 115478
      • Exelixis Clinical Site #101 | Murmansk, Russian Federation, 183047
      • Exelixis Clinical Site #80 | Nizhny Novgorod, Russian Federation, 603137
      • Exelixis Clinical Site #111 | Saint Petersburg, Russian Federation, 197758
      • Exelixis Clinical Site #90 | Saint-Petersburg, Russian Federation, 197758
      • Exelixis Clinical Site #73 | Sochi, Russian Federation, 354057
      • Exelixis Clinical Site #106 | Singapore, Singapore, 169610
      • Exelixis Clinical Site #97 | Singapore, Singapore, 217562
      • Exelixis Clinical Site #116 | Singapore, Singapore, 308433
      • Exelixis Clinical Site #28 | Santander, Cantabria, Spain, 39008
      • Exelixis Clinical Site #21 | Majadahonda, Madrid, Spain, 28222
      • Exelixis Clinical Site #22 | Majadahonda, Madrid, Spain, 28222
      • Exelixis Clinical Site #59 | Pamplona, Navarra, Spain, 31008
      • Exelixis Clinical Site #103 | Barcelona, Spain, 08908
      • Exelixis Clinical Site #164 | Madrid, Spain, 28007
      • Exelixis Clinical Site #63 | Madrid, Spain, 28046
      • Exelixis Clinical Site #168 | Valencia, Spain, 46009
      • Exelixis Clinical Site #45 | Zaragoza, Spain, 50009
      • Exelixis Clinical Site #115 | Basel, Switzerland, 4031
      • Exelixis Clinical Site #172 | Bern, Switzerland, 3010
      • Exelixis Clinical Site #110 | Saint Gallen, Switzerland, 9007
      • Exelixis Clinical Site #61 | Zurich, Switzerland, 8091
      • Exelixis Clinical Site #119 | Changhua, Taiwan, 500
      • Exelixis Clinical Site #162 | Kaohsiung, Taiwan, 833
      • Exelixis Clinical Site #161 | Taichung, Taiwan, 407
      • Exelixis Clinical Site #197 | Tainan City, Taiwan, 704
      • Exelixis Clinical Site #145 | Tainan, Taiwan, 736
      • Exelixis Clinical Site #82 | Taipei, Taiwan, 10002
      • Exelixis Clinical Site #128 | Taipei, Taiwan, 10491
      • Exelixisi Clinical Site #100 | Taipei, Taiwan, 11217
      • Exelixis Clinical Site #94 | Taoyuan, Taiwan, 333
      • Exelixis Clinical Site #96 | Pathum Wan, Bangkok, Thailand, 10330
      • Exelixis Clinical Site #139 | Hat Yai, Songkla, Thailand, 90110
      • Exelixis Clinical Site #143 | Chiang Mai, Thailand, 50200
      • Exelixis Clinical Site #183 | Khon Kaen, Thailand, 40002
      • Exelixis Clinical Site #189 | Istanbul, Instanbul, Turkey, 34098
      • Exelixis Clinical Site #193 | Ankara, Turkey, 06010
      • Exelixis Clinical Site #178 | Ankara, Turkey, 06230
      • Exelixis Clinical Site #173 | Edirne, Turkey, 22030
      • Exelixis Clinical Site #179 | Istanbul, Turkey, 34214
      • Exelixis Clinical Site #180 | Malatya, Turkey, 44280
      • Exelixis Clinical Site #125 | Chernivtsi, Ukraine, 58013
      • Exelixis Clinical Site #122 | Dnipro, Ukraine, 49102
      • Exelixis Clinical Site #123 | Kharkiv, Ukraine, 61070
      • Exelixis Clinical Site #124 | Odesa, Ukraine, 65055
      • Exelixis Clinical Site #138 | Uzhhorod, Ukraine, 88000
      • Exelixis Clinical Site #83 | Bristol, England, United Kingdom, BS2 8ED
      • Exelixis Clinical Site #87 | Cambridge, England, United Kingdom, CB2 0QQ
      • Exelixis Clinical Site #151 | London, England, United Kingdom, NW3 2QG
      • Exelixis Clinical Site #129 | London, England, United Kingdom, W12 0HS
      • Exelixis Clinical Site #192 | Manchester, England, United Kingdom, M20 4BX
      • Exelixis Clinical Site #196 | Belfast, Northern Ireland, United Kingdom, BT9 7AB